[{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"67Cu-Sartate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"67Cu-SARTATE","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"67Cu-SARTATE","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"67Cu-SARTATE","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"67Cu-SARTATE","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Clarity Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Clarity Pharmaceuticals"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Bolus Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Cardinal Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"67Cu-labelled MeCOSar-Tyr3-octreotate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Cardinal Health","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Cardinal Health"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"64Cu-labelled MeCOSar-Tyr3-octreotate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"67Cu SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"67Cu-SAR-bisPSMA","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SAR-bisPSMA","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SAR-bombesin","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Copper-64 SAR Bombesin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"64Cu SAR-bisPSMA","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"67Cu-Sartate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"64Cu-SAR-BBN","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"67SAR-bisPSMA","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Clarity Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Clarity Pharmaceuticals"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"67Cu-SAR-bisPSMA","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Clarity Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : 67Cu-SAR-bisPSMA & 67Cu-SAR-bisPSMA is the study drug that is used to deliver radiation to tumors that express the PSMA protein, being evaluated for metastatic castrate-resistant prostate cancer.

                          Brand Name : 67Cu-SAR-bisPSMA

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 16, 2024

                          Lead Product(s) : 67Cu-SAR-bisPSMA,64Cu-SAR-bisPSMA

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : SAR-bisPSMA (64Cu SAR-bisPSMA) is an injectable radiolabelled compound which are being evaluated for the treatment of prostate cancer and PSMA-expressing metastatic castrate-resistant prostate cancer.

                          Brand Name : SAR-bisPSMA

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 14, 2024

                          Lead Product(s) : 64Cu-SAR-bisPSMA

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : 67Cu-SAR-bisPSMA contains copper-67 and is used to deliver radiation to tumors that express the PSMA protein.Being evaluated for metastatic castrate-resistant prostate cancer.

                          Brand Name : SAR-bisPSMA

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 12, 2024

                          Lead Product(s) : 67Cu-SAR-bisPSMA

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : SAR-bisPSMA (64Cu SAR-bisPSMA) is an injectable radiolabelled compound which are being evaluated for the treatment of prostate cancer and PSMA-expressing metastatic castrate-resistant prostate cancer.

                          Brand Name : SAR-bisPSMA

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 22, 2024

                          Lead Product(s) : 64Cu-SAR-bisPSMA

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the agreement, NorthStar will be responsible for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials being developed in prostate cancer.

                          Brand Name : 67SAR-bisPSMA

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 10, 2024

                          Lead Product(s) : 67SAR-bisPSMA

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : NorthStar Medical Radioisotopes

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : SAR-bisPSMA (64Cu SAR-bisPSMA/67Cu SAR-bisPSMA) are injectable radiolabelled compounds which are being investogated for the treatment of prostate cancer and PSMA-expressing metastatic castrate-resistant prostate cancer.

                          Brand Name : SAR-bisPSMA

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 30, 2023

                          Lead Product(s) : 64Cu-SAR-bisPSMA

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : SAR-bisPSMA (64Cu SAR-bisPSMA/67Cu SAR-bisPSMA) are injectable radiolabelled compounds which are being investogated for the treatment of prostate cancer and PSMA-expressing metastatic castrate-resistant prostate cancer.

                          Brand Name : SAR-bisPSMA

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 30, 2023

                          Lead Product(s) : 64Cu-SAR-bisPSMA,67Cu-SAR-bisPSMA

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : 67Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA is the study drug agent that contains copper-67 & 64 and is used to deliver radiation to tumors that express the PSMA protein. It is being evaluated for the treatment of metastatic castrate-resistant prostate cancer.

                          Brand Name : 64Cu-SAR-bisPSMA

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          November 29, 2023

                          Lead Product(s) : 64Cu-SAR-bisPSMA,67Cu-SAR-bisPSMA

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : SAR-Bombesin is a Targeted Copper Theranostic that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy with broad cancer application. It targets the gastrin-releasing peptide receptor (GRPr).

                          Brand Name : SAR-Bombesin

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          October 03, 2023

                          Lead Product(s) : 64Cu-SAR-BBN

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : SARTATE is highly targeted theranostic radiopharmaceutical. It is developed for diagnosing, staging and subsequently treating cancers that express somatostatin receptor 2. SARTATE product can be used with 64Cu for imaging (64Cu SARTATE) or 67Cu for thera...

                          Brand Name : 67Cu-Sartate

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          August 28, 2023

                          Lead Product(s) : 67Cu-Sartate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : NorthStar Medical Radioisotopes

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank